Fractyl Labs CEO Harith Rajagopalan envisions a scenario in which those with type 2 diabetes don’t have to rely on insulin injections.

Insulin has long been a staple of treatment for type 2 diabetes patients who need to manage their blood sugar levels, but Rajagopalan’s aim is to go beyond that temporary fix.

Trained as a cardiologist, Rajagopalan cared for patients with cardiovascular disease and coexisting type 2 diabetes. While serving as a cardiology fellow at Brigham & Women’s Hospital in Boston, his dad and uncle were diagnosed with type 2 diabetes. That put the wheels in motion for Lexington, Mass.-based Fractyl Labs and its Revita DMR procedure.

Get the full story at our sister site, Drug Delivery Business News.